article · Journal of International Medical Research
ObjectiveThis study aimed to investigate the association of TLR3 single-nucleotide polymorphisms 1337 C/T (rs3775290) and 1234 C/T (rs3775291) with the risk of chronic hepatitis B virus infection.MethodsThis case-control study enrolled 136 participants (66 patients with chronic hepatitis B virus infection (cases) and 70 healthy controls). TLR3 polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism. Demographic/clinical data were collected via standardized questionnaires and analyzed using Statistical Package for Social Sciences (significance level: p < 0.05).ResultsFor TLR3 1337 C/T polymorphism, the CT genotype prevalence was significantly higher in cases (47.0%) than in controls (31.4%) (odds ratio = 0.42, 95% confidence interval: 0.20-0.87, p = 0.0187), while the CC genotype demonstrated protective effects (39.4% in cases vs. 62.9% in controls; odds ratio = 0.26, 95% confidence interval: 0.07-0.94, p = 0.0314). The C allele frequency showed significant between-group differences (odds ratio = 0.46, p = 0.0044). No associations were observed for 1234 C/T single-nucleotide polymorphism (p = 1.0). Biochemical analysis revealed significantly elevated alanine aminotransferase (p = 0.0044) and aspartate aminotransferase (p < 0.0001) levels in cases than in controls.ConclusionsRegarding TLR3 1337 C/T single-nucleotide polymorphism, the CT genotype increases the risk of chronic hepatitis B virus infection (odds ratio = 0.42), while the CC genotype demonstrates protective effects (odds ratio = 0.26) in Sudanese populations, suggesting its utility as a therapeutic target and prognostic marker. No 1234 C/T associations were observed.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1177/03000605251358062
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.